• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ANP 4.92% 5.8¢

ANTISENSE THERAPEUTICS LIMITED - Charts / Financials

Antisense Therapeutics Limited is an Australia-based biotechnology company. The Company... Antisense Therapeutics Limited is an Australia-based biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. Its ATL1103 is in clinical development for acromegaly. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

refresh Created with Sketch. REFRESH
Day
Open 6.0¢   Day High 6.0¢   Day Low 5.6¢
Daily Volume 869280
Bids   Sellers
Number Price Volume   Number Price Volume
1 5.7¢ 147501   1 6.0¢ 172313

Directors & Senior Management

Dr. James B. Garner Chief Executive Officer, Managing Director, Executive Director
Mr. Phillip Hains Chief Financial Officer, Joint Company Secretary
Dr. Anthony Filippis Chief Commercial Officer
Dr. Andrew Mckenzie Clinical Development Director
Dr. George Tachas Director - Drug Discovery and Patents
Ms. Alicia Mellors Joint Company Secretary
Dr. Charmaine Gittleson Non-Executive Independent Chairman of the Board
Dr. Ben Gil Price Non-Executive Independent Director

Data source: Refinitiv

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.